Sterling Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Sterling Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.63K	Sell	540 -71	-12%	-$560	﹤0.01%	2782
2026 Q1	$4.72K	Sell	611 -350	-36%	-$2.55K	﹤0.01%	2763
2025 Q4	$5.89K	Sell	961 -138	-13%	-$1.49K	﹤0.01%	2836
2025 Q3	$20.3K	Buy	1,099 +654	+147%	+$10.5K	﹤0.01%	2134
2025 Q2	$5.79K	Buy	445 +381	+595%	+$4.5K	﹤0.01%	2430
2025 Q1	$678	Sell	64 -41	-39%	-$651	﹤0.01%	2914
2024 Q4	$1.78K	Buy	105 +76	+262%	+$1.43K	﹤0.01%	2810
2024 Q3	$673	Buy	+29	New	+$620	﹤0.01%	2731

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sterling Capital Management's ARCT Position: Q2 2026 in Review

Sterling Capital Management reduced its Arcturus Therapeutics (ARCT) stake by 12% in Q2 2026, selling an estimated $560 and leaving 540 shares worth $3.63K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Sterling Capital Management first reported a position in ARCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.3K in Q3 2025. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Sterling Capital Management held 540 shares of Arcturus Therapeutics worth $3.63K as of Q2 2026.
Sterling Capital Management sold 71 Arcturus Therapeutics shares in Q2 2026, an estimated $560.
Arcturus Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2782 holding.
Sterling Capital Management first reported a position in Arcturus Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Arcturus Therapeutics position peaked at $20.3K in Q3 2025.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.